Sotera Health (SHC) Q3 2026 Earnings Call Transcript
Sotera Health (SHC) reported Q3 2026 revenue growth of 4.4% to $325M and adjusted EBITDA growth of 4% to $171M. Sterigenics grew 8.2%, Nelson Labs 9.2%, and Nordion declined 11.5%. The company reaffirmed its 2026 revenue and adjusted EBITDA outlook, expecting 5.25-6.75% and 5.75-7.25% growth, respectively. Adjusted EBITDA margins expanded sequentially by 100 basis points to 52.5%.
How this was made

The 30-second read
Why it matters
Earnings reaffirmation supports current valuation; no major surprises but solid execution may sustain current price levels.
Market read
First earnings report of the quarter; provides fresh data for traders to adjust positions.
What to watch
Potential softness in med device market could pressure Sterigenics segment later.
Background
Sotera Health operates Sterigenics, Nelson Labs, and Nordion segments providing safety testing and sterilization services.
Ticker impact
Sotera Health disclosed Q3 2026 results with revenue $325M, EPS $0.20 and reaffirmed full-year guidance.
likely modest upside as market prices in solid growth and reaffirmed outlook
First earnings release with fresh numbers; solid performance but no surprise guidance change.
Market effects
Positive for healthcare services and contract testing sector as earnings show resilience.
U.S. healthcare services stocks may see modest lift.
Limited to investors tracking US healthcare service providers.
Counterpoint
Guidance unchanged could signal limited growth; investors may wait for next quarter for upside.
Key entities
- CompanySotera Health
Provider of healthcare product safety and sterilization services.



